Tahir BURAN, Elmas KASAP, Gamze GÖKSEL ÖZTÜRK, Burcu ALMACAN İNCE

Nadir Karaciğer Metastazı Bulunan Nöroendokrin Tümör Olgusu

Nöroendokrin tümörler, nöroendokrin sistem hücrelerinden köken alan heterojen bir neoplazm grubundan oluşmaktadırlar. Bu olgu sunumunda diffüz karaciğer metastazı ile seyreden non-fonksiyone bir nöroendokrin tümör olgusu tartışılmıştır. Kliniğimize karın ağrısı ve karında şişlik şikayetleri ile başvuran 61 yaşındaki erkek hastanın yapılan radyolojik ve nükleer tıp incelelemelerinde karaciğerde diffüz metastazla uyumlu çok sayıda hipodens kitle lezyonları saptandı. Yapılan karaciğer biyopsisi, hepatik nöroendokrin tümör metastazı ile uyumlu bulundu. Diffüz karaciğer tutulumu birlikte hastanın yaşının ileri olması nedeni ile cerrahi rezeksiyon düşünülmedi. Hastaya uzun etkili somatostatin analoğu başlandı. Takiplerde hastanın semptomları geriledi Sonuç olarak nadir görülen nöroendokrin tümörleri yavaş seyrinin aksine yakın zamana kadar asemptomatik seyretmesine karşın, yaygın karaciğer metastazıyla birlikte non-fonksiyone olarak karşımıza çıkabileceği göz önünde bulundurulmalıdır.

A Rare Case of Neuroendocrine Tumor with Liver Metastasis

Neuroendocrine tumors arise from neuroendocrine system cells, and constitute a heterogeneous group of neoplasms. In this case report, a case of non-functional neuroendocrine tumor presented with diffuse liver metastases is discussed. Radiological and nuclear medicine examinations of a 61-year-old male patient admitted to our clinic with complaints of abdominal pain and abdominal swelling revealed multiple hypodense mass lesions consistent with diffuse metastasis in the liver. Liver biopsy showed neuroendocrine tumor in hepatic metastases. Surgical resection as a treatment option was not applicable because of her advanced age and diffuse liver metastases. Long-acting somatostatin analogue was prescribed for the patient. In the follow-up, despite reduction in the patient’s symptoms. In conclusion, it should be kept in mind that although neuroendocrine tumors, which are rare, have been asymptomatic until recently, despite their slow course, they may present as non-functional with extensive liver metastasis.

PDF

___

1. Solcia, E, Kloppel, G, Sobin, L.H, Histological typing of endocrine tumours, Second edition WHO Heidelberg:Springer-Verlag, 2000, 38-74.
2. Rindi, G, Villanacci, V, Ubiali, A, Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors, Digestion, 2000, 62, 19-26.
3. Adam, M, Douglas, G.A, Neuroendocrine Tumors: Review and Clinical Update, 2007, 51, 12-20.
4. Taal, B.G, Visser, O, Epidemiology of neuroendocrine tumours, Neuroendocrinology, 2004, 80, 3–7.
5. Sutcliffe, R, Maguire, D, Ramage, J et al, Management of neuroendocri liver metastases, American Journal of Surgery, 2004, 187, 39–46.
6. Mazzaferro, V, Pulvirenti, A, Coppa, J, Neuroendocrine tumor metastatic to the liver: how to select patients for liver transplantation, Hepatology, 2007, 47, 460–466.
7. Benevento, A, Boni, L, Frediani, L, et al, Result of liver resection as treatment for metastases from noncolorectal cancer, Journal of Surgical Oncology, 2000, 74, 24-29.
8. Blonski, W.C, Reddy, K.R, Shaked, A et al, Liver transplantation for metastatic neuroendocrine: A case report and review of the literature, World Journal of Gastroenterology, 2005, 11, 7676–7683.
9. Frilling, A, Rogiers, X, Malago, M et al, Liver transplantation in patients with liver metastases of neuroendocrine tumors, Transplantation Proceedings, 1998, 30, 3298-3300.
10. Ahlman, H, Friman, S, Cahlin, C et al, Liver transplantation for treatment of metastatic neuroendocrine tumors, Annals N.Y Academy Science, 2004, 1014, 265-269.
11. Sarmiento, J.M, Que, F.G, Hepatic surgery for metastases from neuroendocrine tumors, Surgical Oncology of Clinics of North America, 2003, 12, 231-242.
12.Nobels FRE, Kwekkeboom DJ, Bouillon R, et al. Chromogranin A: its clinical value as marker of neuroendocrine tumors. European Journal of Clinical Investigation 1998;28:431-438
13. Sekiya K, Ghatei MA, Salahuddin MJ, et al. Production of GAWK (Chromogranin-B 420-493)-like immunoreactivity by endocrine tumors and its possible diagnostic value. Journal of Clinical Investigation 1989;83:1834-1842.
14. Chamberlain RS, Canes D, Brown KT, Y et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? Journal of American College Surgery, 2000; 190:432-445.
15. Plöckinger, U, Wiedenmann, B. Diagnosis of non-functioning neuroendocrine gastro-enteropancreatic tumours. Neuroendocrinology, 2004, 80, 35–38.
16. Chatal, J.F, Le Bodic M.F, Kraeber-Bodere, F et al, Nuclear medicine applications for neuroendocrine tumors, World Journal of Surgery, 2000, 24, 1285-1289.
17. Olausson, M, Friman, S, Cahlin, C, et al, Indications and resuls of liver transplantation in patients with neuroendocrine tumors, World Journal of Surgery, 2002, 26, 998-1004.
18. Strosberg, J, El-Haddad, G, Wolin, E et al, Phase 3 trial of 177lu dotatate for midgut neuroendocrine tumors, New Engandl Journal of Medicine, 2017, 376, 125- 135.
19. Sanli, Y, Garg, I, Kandathil, A et al, Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT, FOCUS ON: Nuclear Medicine and Molecular Imaging, 2018, 211, 267-277.